News

US–Iran Escalation Raises Supply Chain Concerns for Indian Pharma Industry

Rising tensions in West Asia prompt Indian drugmakers to review logistics, energy costs and export exposure amid global uncertainty.

• By PharmaNews Live Desk
• New Delhi
• Mar 02, 2026

News

The escalating tensions between the United States and Iran have triggered fresh concerns within India’s pharmaceutical sector, with industry stakeholders closely tracking potential disruptions to trade routes, raw material supplies and export markets.

Although no immediate impact has been reported, analysts say that prolonged instability in West Asia — a key transit corridor and global energy hub — could affect India’s pharmaceutical exports and raise operational costs.

Shipping Routes and Logistics Under Watch

Industry representatives note that any disruption in the Strait of Hormuz, a critical maritime passage for global oil shipments and cargo movement, may result in higher freight charges and longer delivery timelines. India exports a significant volume of pharmaceutical formulations and generic medicines to markets across West Asia, Africa and Europe, many of which depend on shipping routes passing through the region.

Executives associated with pharmaceutical export bodies say companies are reviewing contingency logistics plans to mitigate potential delays. An industry official said the situation is being closely monitored and that while supplies remain stable at present, prolonged escalation could strain shipping schedules and push up insurance premiums.

Energy Prices and Input Costs

The pharmaceutical industry, which relies on energy-intensive manufacturing and petrochemical derivatives, is also vulnerable to fluctuations in crude oil prices. A sustained spike in global oil prices could translate into higher packaging, transportation and production costs.

Market analysts point out that rising energy prices may indirectly increase the cost of active pharmaceutical ingredients (APIs), solvents and other intermediates. One industry observer noted that volatility in crude prices has a cascading effect across the value chain and could impact margins, particularly for export-oriented generic drug manufacturers.

Exposure to West Asian Markets

West Asia remains a significant market for Indian pharmaceuticals, with several countries in the region importing essential medicines, hospital supplies and chronic therapy drugs from Indian manufacturers. Industry data indicate that the region accounts for a meaningful share of India’s formulation exports.

Companies with trade exposure to Iran have historically faced challenges linked to sanctions and payment mechanisms. Financial restrictions, currency volatility and compliance requirements have complicated transactions in the past. Analysts suggest that renewed geopolitical tensions could further complicate settlement processes if additional restrictions are introduced.

Government Monitoring and Industry Preparedness

Government authorities are understood to be monitoring developments, particularly with regard to supply chain stability and export commitments. India, widely known as the “pharmacy of the world,” plays a critical role in supplying affordable generic medicines to global markets.

Industry bodies say companies have diversified sourcing strategies in recent years, including efforts to reduce dependence on single geographies for critical raw materials. A senior executive remarked that while the sector has built resilience following previous global disruptions, including the pandemic, geopolitical instability remains an external risk factor.

Balancing Risks Amid Global Uncertainty

Despite the heightened tensions, pharmaceutical exports from India continue without disruption. Stakeholders maintain that unless the situation escalates into a broader regional conflict, the impact may remain limited to short-term cost volatility and logistical adjustments.

For now, the industry is adopting a cautious approach. An export council representative said there is no immediate disruption but emphasized that global supply chains are deeply interconnected and that prolonged conflict in a strategic region can reverberate across industries.

With global markets already facing economic headwinds and supply chain recalibrations, the unfolding US–Iran tensions add another layer of complexity for India’s pharmaceutical sector, underscoring the need for strategic planning and close monitoring in the weeks ahead.